VAERS reports by lot

Pfizer COVID-19 lot GJ6742: VAERS reports

464 VAERS reports list lot GJ6742 as a Pfizer COVID-19 vaccine, received between 2022-10-04 and 2024-04-18. Data: VAERS public files through 31 December 2024 (site extract 2026-07-04).

Read this first. VAERS accepts reports from anyone, and a report does not establish that the vaccine caused the event. A lot's report count mostly reflects how many doses it contained, when it was used and who received it; no administered-dose counts are published for this lot, so counts are not rates and cannot rank lots against each other. Lot numbers in VAERS reports are typed by reporters and are sometimes wrong.
464
Reports
13%
Marked serious
4
With a death outcome
19
Months with reports

Symptom categories in these reports

A report can mention several categories, so the counts add up to more than the number of reports.

CategoryCount%
General / Systemic (non-local)24323%
Cardiac / Cardiovascular15615%
Neurological14414%
Gastrointestinal11811%
Respiratory10610%
Injection-site / Local reaction717%
Musculoskeletal666%
Dermatological (non-injection-site)454%
Allergic / Anaphylactic343%
Thrombotic / Hematological262%
Psychiatric / Neuropsychiatric202%
Autoimmune / Immune-mediated101%
Reproductive / Menstrual10%

Where reports came from

U.S. state of the reporter, where given (top 12).

Florida79
Arizona41
California34
Connecticut21
Indiana21
Massachusetts19
Pennsylvania17
Illinois17
New York13
Michigan12
Washington12
Texas11

Reports by month received

2022-1023
2022-1110
2022-1261
2023-01100
2023-0241
2023-0334
2023-0415
2023-05118
2023-0621
2023-077
2023-085
2023-092
2023-105
2023-114
2023-126
2024-013
2024-021
2024-035
2024-043

Products recorded with this lot

Manufacturer and product as reported in VAERS. Reports listing the lot under more than one product are counted once.

Related

Source: VAERS public data (CDC/FDA), grouped by manufacturer and lot by the Open Source Medicine Foundation; extract 2026-07-04 16:35 UTC. Not medical advice. Report errors via contact.